FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

693 letters match. Newest first.

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Bharat Overseas Inc.

    FDA warns New York importer Bharat Overseas for having no foreign supplier verification program for its imported foods.

    Medium
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. Medline Inc

    FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.

    High risk
  5. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  6. Aversa's Italian Bakery

    FDA warns Aversa's Italian Bakery over missing food safety plan and undeclared sesame/milk allergens in ready-to-eat rolls.

    High risk
  7. HealthPartners Neuroscience Center Research and Innovation

    FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

    Medium
  8. Dough-To-Go, Inc.

    FDA warned Dough-To-Go of Santa Clara, CA after an inspection found insanitary conditions and unused food safety controls at its baked goods plant.

    High risk
  9. Boba Factory Inc

    Boba Factory Inc lacked required foreign supplier verification programs for imported non-dairy creamer, flavoring syrup, and dry custard mix.

    Medium
  10. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk
  11. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  12. Best Buy Bones, Inc.

    Best Buy Bones pet treats were found with Salmonella and serious animal-food safety and CGMP violations.

    High risk
  13. Shineluck Foods, Inc.

    FDA warns Shineluck Foods that its mung bean sprouts were held under insanitary conditions with pathogen testing and monitoring failures.

    High risk
  14. Zap Expo Center Inc.

    Zap Expo Center Inc. lacked required supplier checks for imported foods, FDA found.

    Medium
  15. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  16. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk
  17. Sahara Enterprise Inc.

    FDA warns Sahara Enterprise Inc. over missing FSVP for imported phyllo dough, Turkish delight, and baklava.

    Medium
  18. JW Nutritional LLC

    FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.

    High risk
  19. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  20. OptiHealth Products, Inc.

    FDA warned OptiHealth Products over website claims that Super Antioxidant (OPCXtra) is a drug for diseases like diabetes and Alzheimer's.

    Low
  21. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  22. Minh Phung, Inc.

    FDA warns Minh Phung, Inc. over insanitary conditions and time-temperature abuse in refrigerated rice noodles and rice cakes.

    High risk
  23. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  24. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  25. The Fish Aid

    FDA warned The Fish Aid it sells unapproved, unlisted antibiotics for aquarium fish and birds without veterinary oversight.

    High risk
  26. Baja Fresko Distributors Inc.

    FDA warned Baja Fresko Distributors it lacked FSVP records for imported squash, cucumbers, and husk tomatoes.

    Medium
  27. JMT Inter LLC

    FDA warned Delaware food importer JMT Inter LLC for not keeping or sending required records on imported soft drinks.

    Medium
  28. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  29. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk
  30. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  31. Unetixs Vascular, Inc.

    Unetixs Vascular marketed modified ROODRA and 2CP vascular diagnostic devices without required FDA clearance.

    High risk
  32. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  33. DO&CO Aktiengesellschaft/DO&CO, Inc.

    DO&CO airline catering facilities in New York and Michigan had repeated Listeria monocytogenes contamination and sanitation failures.

    High risk
  34. ISA Produce Corporation

    ISA Produce Corporation lacked FSVP records for imported fresh produce, FDA says after February 2026 inspection.

    High risk
  35. Hearthy Foods, Inc.

    FDA cited Hearthy Foods after an inspection for CGMP violations in RTE whey protein and dietary supplements, including allergen and pest issues.

    High risk
  36. Intelligent Remedies, Inc.

    FDA warned Intelligent Remedies that disease-treatment claims make nine products unapproved new drugs.

    High risk
  37. South Bay Cold Storage & Handling, Inc.

    FDA warned South Bay Cold Storage & Handling that its seafood safety plans and sanitation were inadequate for crab, smoked salmon and scombroid fish.

    High risk
  38. Supersmart USA, LLC

    FDA says Supersmart USA sold dietary supplements with disease-treatment claims, making them unapproved and misbranded drugs.

    Low
  39. Min Jiang Food Store Inc dba Koi Koi Trading

    FDA found Listeria on food-contact surfaces at Koi Koi Trading's ready-to-eat seafood plant and cites seafood HACCP failures.

    High risk
  40. RSV Pita, Inc. DBA Pita Pan Bakery

    FDA warns Pita Pan Bakery that ready-to-eat pita, bagels and challah were made under insanitary conditions and had undeclared allergens.

    High risk
  41. Aaa International Seafood Corp.

    Aaa International Seafood Corp. fresh tuna and salmon were adulterated due to seafood HACCP and importer verification failures.

    High risk
  42. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  43. The Wilatta Group Inc.

    FDA warns The Wilatta Group Inc. that it imported foods without required foreign supplier verification programs.

    Medium
  44. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  45. Intas Pharmaceuticals Limited

    FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

    High risk
  46. Nupack Inc.

    FDA warned Nupack Inc. that its dietary supplements were unapproved drugs and made without required manufacturing-practice records.

    High risk
  47. SaNOtize

    FDA warns SaNOtize that NOWONDER Nasal Cleanser is an unapproved new drug sold in the U.S. with antiviral claims.

    Medium
  48. Par Health USA, LLC & Endo USA, Inc.

    FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.

    High risk
  49. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk
  50. Pro Numb Tattoo Numbing Spray, LLC

    FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.

    High risk